Sanofi reported a positive Phase 3 outcome for Lumizyme’s successor in infants with severe Pompe disease, supporting a potential U.S. label expansion. The company said its enzyme replacement therapy met expectations in a registrational trial, setting up the next regulatory steps for an expanded indication. For lysosomal storage disorder developers and payers, pediatric label expansions can shift demand and budget assumptions quickly once regulatory approvals land, especially when disease severity and age band definitions expand. While details of the endpoints and comparative results were not included in the prompt, the reported “Phase 3 test passed” signal is a near-term catalyst for commercialization planning.